Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective to evaluate venous thromboembolism (VTE) incidence and risk factors in patients (pts) with non-small cell lung cancer (NSCLC) receiving front-line therapy

Next Previous
Search
Trial Profile

A retrospective to evaluate venous thromboembolism (VTE) incidence and risk factors in patients (pts) with non-small cell lung cancer (NSCLC) receiving front-line therapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary) ; Alectinib (Primary) ; Atezolizumab (Primary) ; Avelumab (Primary) ; Bevacizumab (Primary) ; Ceritinib (Primary) ; Crizotinib (Primary) ; Durvalumab (Primary) ; Erlotinib (Primary) ; Etoposide (Primary) ; Gefitinib (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary) ; Osimertinib (Primary) ; Pembrolizumab (Primary) ; Pemetrexed (Primary) ; Taxanes (Primary)
  • Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 01 Dec 2021 Primary endpoint (cumulative incidence of VTE at 6- and 12-months) has been met as per Results published in the Thrombosis Research
    • 01 Dec 2021 Results assessing VTE incidence rates and identify predictive factors in NSCLC patients receiving first-line systemic therapies, including immune checkpoint inhibitors published in the Thrombosis Research
    • 13 Jun 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top